

Table 1: Case reports- ALK-positive Lung Adenocarcinoma in Adolescents.

Author	Age/Gender	TNM stage	First line treatment	Outcome
Balzer 2018	14/F	IV	Alectinib	Alive with controlled disease (9 months)
Usmani 2018	18/M	IV	Alectinib	Alive with controlled disease (8 months)
Scarpino 2016	17/M	IV	Crizotinib	Died from disease (7 months)
Kim 2012	14/F	IV	Crizotinib	Alive with controlled disease (16 months)